Antitumor effect of anti-CCR4 antibody in head and neck cancer
| Project/Area Number |
26463042
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Nagasaki University (2016)
Okayama University (2014-2015) |
|---|
Principal Investigator |
DOMAE Shohei 長崎大学, 病院(歯学系), 講師 (70397892)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
小野 俊朗 岡山大学, 自然生命科学研究支援センター, 教授 (50185641)
花房 直志 岡山大学, 自然生命科学研究支援センター, 准教授 (00228511)
榮川 伸吾 岡山大学, 医歯薬学総合研究科, 助教 (40635265)
|
|---|
| Research Collaborator |
KUNISADA Yuki
TAKAKURA Hiroaki
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | CCR4分子 / 制御制T細胞 / 腫瘍浸潤リンパ球 / 頭頸部癌 / CCR4 / PD-L1 / 制御性T細胞 / 抗体療法 |
|---|
| Outline of Final Research Achievements |
CCR4 expressing FoxP3+CD4 regulatory T cells (Treg) depletion using humanized anti-CCR4 monoclonal antibodies may enhance the host immune response against tumors. The current ongoing clinical trial investigates the use of humanized anti-human-CCR4 monoclonal antibody in the treatment of solid tumors. CCR4 expressing stroma infiltrating lymphocytes were detected in 32 of 42 (76.2%) head and neck cancer samples and were correlate with CCL22/MDC. CCR4 expressing tumor cells were detected in only 7 of 42 (16.7%) same samples. There was no markedly enhancement of antitumor effect by anti-CCR4 antibody in CCR4 expressing tumor cells.
|
Report
(4 results)
Research Products
(8 results)
